Skip to main content
UNIVERSAL BIOSENSORS INC. logo

UNIVERSAL BIOSENSORS INC. — Investor Relations & Filings

Ticker · UBI ISIN · AU000000UBI2 LEI · 9845006ABC71C514C696 ASX Manufacturing
Open in API
Filings indexed 958 across all filing types
Latest filing 2024-05-07 Regulatory Filings
Country AU Australia
Listing ASX UBI

About UNIVERSAL BIOSENSORS INC.

https://universalbiosensors.com/

Universal Biosensors Inc. specializes in the research, development, and manufacture of electrochemical biosensor systems for point-of-care testing. The company leverages a proprietary technology platform to deliver rapid, accurate diagnostic results across various sectors, including healthcare and food and beverage. Its core product offerings include the Xprecia Prime system for coagulation monitoring and the Sentia platform, which provides automated laboratory-grade analysis for the wine industry, measuring parameters such as free sulfur dioxide, malic acid, and glucose. Universal Biosensors focuses on miniaturizing complex laboratory tests into portable, easy-to-use devices, utilizing multi-layer test strip architecture and sophisticated electrochemical detection methods to improve testing efficiency and accessibility in decentralized settings.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - UBI 7 pages 21.5KB
Regulatory Filings Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the securities to be quoted, their issue dates, distribution schedules, and issued capital following quotation. It references previous announcements (Appendix 3B) related to the securities issuance. The document is regulatory in nature, focused on the listing and quotation of securities rather than financial results, management changes, or other report types. It is not a financial report, earnings release, or management discussion. It is a formal regulatory filing related to capital markets compliance and securities quotation. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7599 characters) and content confirm it is not merely an announcement of a report but a regulatory form submission.
2024-05-07 English
Application for quotation of securities - UBI 6 pages 18.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Universal Biosensors Inc. regarding the application for quotation of securities on the ASX. It details the securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document is a formal application related to the listing or quotation of securities rather than a financial report, earnings release, or management discussion. It is not a report itself but an announcement related to capital market activities, specifically the quotation of securities. This fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital changes such as securities quotation applications.
2024-05-07 English
Top 20 and Distribution Schedule for Quoted Options 3 pages 235.4KB
Major Shareholding Notification Classification · 100% confidence The document provides detailed information about the top 20 holdings of Universal Biosensors Inc as of a specific date (08-05-2024). It lists major shareholders, their securities, and percentage holdings, as well as an analysis of holdings by range. This type of document is a notification of significant share ownership levels and changes in shareholding distribution. It does not contain financial statements, management discussion, or other report types. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding data, confirming this classification.
2024-05-07 English
Q1 2024 Results 34 pages 2.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and explicitly states it is a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended March 31, 2024. It contains detailed unaudited financial statements including balance sheets, statements of comprehensive income, changes in stockholders' equity, cash flows, and notes to the financial statements. It also includes management's discussion and analysis, risk factors, legal proceedings, and other information typical of a quarterly report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-05-01 English
Q1 2024 Results Presentation - 31 March 2024 8 pages 694.3KB
Investor Presentation Classification · 95% confidence The document is titled 'Universal Biosensors, Inc. Update Q1 2024' and contains detailed operational highlights, sales growth figures, product development updates, and forward-looking statements. It includes financial metrics such as cash reserves and expense reductions, as well as commercial progress and negotiations. The content is structured as a presentation with disclaimers, forward-looking statements, and market data, typical of investor presentations. It does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR), nor is it a brief earnings release (ER) or annual report (10-K). The document is too long and detailed to be a simple announcement or regulatory filing. The presence of slides, charts, and forward-looking statements aligns with an Investor Presentation (IP). Therefore, the document is best classified as an Investor Presentation (IP).
2024-05-01 English
March 2024 Quarterly Activity Report and Appendix 4C 7 pages 368.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'March 2024 Quarterly Activity Report' and includes detailed financial data such as cash flow statements, cash equivalents, financing activities, and operational cash flow for the quarter ended 31 March 2024. It references ASX Listing Rules Appendix 4C, which is a standard quarterly cash flow report format for entities listed on the Australian Securities Exchange. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement or a certification but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.